2.1
Durvalumab (Imfinzi, AstraZeneca) in combination with gemcitabine and cisplatin is indicated for 'the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer'.
2 Information about durvalumab plus gemcitabine and cisplatin
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for durvalumab.
Price
2.3
2.4
The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.